However, there is a problem with LDL-P: most doctors will not pull it for you and it is currently pretty expensive to pull yourself. Many physicians do not yet understand the importance of LDL-P and are not interested in “unnecessary testing”, i.e. testing you before develop angina or drop dead from a heart attack! In my opinion, LDL-P should a part of every man’s yearly physical. Unfortunately, if a man tries to pull LDL-P himself, the cheapest cost from what I have seen is in the $125-$150 range.
The good news is that there is another marker out there that one can use in place of LDL-P: apolipoprotein B (apoB). From all I have read – of course do your own research – this number essentially parallels LDL-P and it is MUCH cheaper. For example, you can get this at Health Tests Direct for $35, assuming you don’t live in one of the states that doesn’t allow testing. See my page on Testosterone Labs for more information.
“Although LDL cholesterol (LDL-C) is associated with an increased risk of coronary heart disease, other lipoproteins and their constituents, apolipoproteins, may play an important role in atherosclerosis. Elevated levels of apolipoprotein (apo) B, a constituent of atherogenic lipoproteins, and reduced levels of apo A-I, a component of anti-atherogenic HDL, are associated with increased cardiac events.” 
So why should a man be interested in managing his arterial plaque? Well, besides the fact that he could drop dead from a heart attack, plaque is also tied to nitric oxide production and erectile function. Yes, as plaque builds up in those penile arteries, things will softer and slower in the bedroom.
That said, it’s better safe than sorry and so you may want to shoot for this target. However, keep in mind that Dr. Davis recommends LDL-C levels below 60 mg/dl and I have seen other reliable sources recommend between 70 and 80 for plaque reversal.
2. Go For The Top Five Percent. According to some Lipid Center data, if you want to be in the top five percent of apoB scores, you would need to have a level of 62 mg/dl or below.  This is probably a reasonably solid number as about 5 percent of Americans have no atherosclerosis and notice that it corresponds fairly closely to Dr. Davis’ 60 threshold. If you want to be in the top 2 percent, you would have to be well below that at 54 mg/dl according to the same report.
3. ~100 mg/dl in Higher Cholesterol Patients?. There is an interesting study out there that put patients with higher cholesterol on either a statin or high dose niacin. You may recongize these as the two agents that the Plaque Regressers Dr. Gould and Dr. Davis use on most of their patients. A statin works primarily by lowering the over LDL numbers and niacin by moving the LDL away from a “pattern B,” i.e. less small particle LDL and triglcyerides. What is interesting is that both strategies decreased narrowing of the arteries in a multiyear study even though their apoB levels were not really that low. ApoB levels were 103 and 111 mg/dl in the lovastatin and niacin groups, respectively and yet they still experienced plaque regression.  Is it easier for higher cholesterol patients to regress plaque? I don’t know, but I would aim for lower apoB numbers to play it safe.
4 Verify with an LDL-P Blood Draw. You can also pull your LDL-P (LDL Particle Count) and verify using that as mentioned above. To get an idea for levels to reverse plaque using this marker, see my page https://www.peaktestosterone.com/l and LDL-P Particle Count Levels.
DIET ALONE? Can you achieve a satisfactory apoB score with just diet alone. I can tell you that I am currently on a low glycemic, low fat diet and exercizing and hour per day. Doing just this I have been able to get my apoB down to 68 mg/dl without niacin or a statin. This is a good start in my opinion, but I’d like to drop it below 65 if at all possible.
2) Track Your Plaque, by Dr. William Davis, iUniverse, p. 93.
3) N Engl J Med, 1990; 323:1289-1298, “Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B”
4) J Intern Med, 2004 Feb, 255(2):188-205, “Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy.”